LSD Treatment for Persons With Alcohol Use Disorder (LYSTA)

This double-blind study (n=128) will investigate if LSD (150-250μg, 2x) will be effective in treating alcoholism (AUD). This will be compared to an ‘active’ placebo of 10μg LSD. The study, when conducted, will be the largest modern study of LSD for AUD.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account
Status Not yet recruiting
Start date 01 January 2023
End date 01 January 2025
Chance of happening 100%
Phase Phase II
Design Blinded
Type Interventional
Generation First
Participants 128
Sex All
Age 25- 99
Therapy Yes

Trial Details

Alcohol use causes more overall harm than any other drug and is the seventh leading risk factor for both deaths and disability-adjusted life years. Alcohol use disorders (AUD) are among the most common and undertreated mental disorders in developed countries. Pharmacological and psychotherapeutic treatments only show limited efficacy and around 60% of the patients relapse in short-term after withdrawal. Lysergic acid diethylamide (LSD) was extensively investigated in the 1950s and 1960s and became one of the best-studied psychoactive substances with several thousands of early scientific reports. Specifically, the use of LSD in the treatment of AUD was investigated extensively. A pooled analysis of six historical clinical trials demonstrated, that a single dose of LSD significantly reduced alcohol use at three and six months after LSD administration and the improvements surpassed treatment with established psychopharmacological interventions. However, these historical studies do not meet today's methodological standards which limits the validity of these findings. Well-designed studies are needed to further investigate this promising treatment approach. Therefore, the present study aims to evaluate safety and efficacy of LSD for the treatment of AUD. The trial has a double-blind, active placebo-controlled, randomized, parallel design and will be conducted in three specialized treatment centers for addictive disorders in Switzerland. The study will include 128 patients after withdrawal treatment and will primarily assess the efficacy of LSD for relapse prevention after standard detoxification. Patients will be treated using a 1:1 allocation. In the first session, patients in the treatment group will receive a dose of 150 µg LSD, followed by another 150 µg or 250 µg LSD in the second session, which will take place approximately 4 weeks after the first session. The primary outcome is the mean of percent heavy drinking days after administration of two doses of LSD at 3 months' follow-up. Additionally, other alcohol associated parameters and associated common comorbidities as well as potential predictors and mediators for treatment response will be assessed.

NCT Number NCT05474989

Sponsors & Collaborators

University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.

Data attribution

A large set of the trials in our database are sourced from (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.